{
  "contract_id": "ParatekPharmaceuticalsInc_20170505_10-KA_EX-10.29_10323872_EX-10.29_Outsourcing Agreement_cleaned",
  "original_file": "ParatekPharmaceuticalsInc_20170505_10-KA_EX-10.29_10323872_EX-10.29_Outsourcing Agreement_cleaned.txt",
  "chunk_size": 1000,
  "chunk_overlap": 200,
  "total_chunks": 95,
  "chunks": [
    "Exhibit 10.29\nExecution Version\nOutsourcing Agreement\nBetween\nParatek Pharmaceuticals, Inc.\nand\n[SECTION] CARBOGEN AMCIS AG\nDate\n30 December 2016\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n1.1 Definitions 7\n1.2 Other Definitions 11\n1.3 Currency 11\n1.4 Headings 11\n1.5 Exhibits 11\n1.6 Applicable Law 12\nArticle 2 Term 12\n2.1 Term 12\n2.2 Effect of Expiration on Purchase Orders 12\nArticle 3 Supply of Product 12\n3.1 Supply of Product 12\n3.2 Manufacturing Services 13\n3.3 Supply of Materials and Customer Material 13\n3.4 Production Capacity 15\n3.5 Processing Changes 15\n3.6 Monitoring of Facilities 16\n3.7 Subcontracting 16\n3.8 [* * *] 16\n3.9 [* * *] 17\n3.10 Territory Expansion 17\n3.11 Supply to Customer Licensees 17\n3.12 Alternative Supply 17\nArticle 4 Forecasts 18\n4.1 Short Term Rolling Forecasts 18\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n5.1 Release Testing 19\n5.2 Additional Release Testing 19\n5.3 Retention Samples 19\n5.4 Stability Testing 20",
    "4.1 Short Term Rolling Forecasts 18\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n5.1 Release Testing 19\n5.2 Additional Release Testing 19\n5.3 Retention Samples 19\n5.4 Stability Testing 20\n5.5 Reference Standards 20\n5.6 Preparation of Process Qualification 20\nArticle 6 Purchase Orders 20\n6.1 Placement of Purchase Orders 20\n6.2 Acceptance of Orders 20\n6.3 Delays 21\n6.4 Cancellation of Purchase Orders 21\n6.5 Material Failure of Supply 21\n6.6 Services 21\nArticle 7 Shipment of Product 22\n7.1 Storage of Product 22\n7.2 Release and Shipment of Product 22\n7.3 Documentation 23\n7.4 Steering Committee 23\nArticle 8 Acceptance of Shipments 23\n8.1 Acceptance of Shipments 23\n8.2 Dispute of Rejected Product 24\n8.3 Remedies 24\nArticle 9 Fees 25\n9.1 Fees 25\n9.2 Adjustments to Fees 25\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\nArticle 10 Invoicing and Payment 26\n10.1 Issuance of Invoices 26\n10.2 Invoice Contents 26\n10.3 Delay of Shipment 27\n10.4 Payment of Invoices 27",
    "Source: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\nArticle 10 Invoicing and Payment 26\n10.1 Issuance of Invoices 26\n10.2 Invoice Contents 26\n10.3 Delay of Shipment 27\n10.4 Payment of Invoices 27\nArticle 11 Intellectual Property 27\n11.1 Title 27\n11.2 No Grant of Rights 27\n11.3 Grant of License by Customer 28\n11.4 Ownership of Inventions 28\n11.5 Patents to Inventions 28\n11.6 No Use of Trademarks 28\n11.7 [* * *] 28\n12.2 Disclosure with Consent 29\n12.3 Publicity 29\n12.4 Disclosure Required by Law 30\n12.6 Duration of Obligation 30\nArticle 13 Representations, Warranties and Covenants 31\n13.1 Supplier's Representations, Warranties and Covenants 31\n13.2 Customer's Representations, Warranties and Covenants 32\n13.3 No Other Warranty 32\n13.4 No Consequential Damages and Limitation of Liability 33\nArticle 14 Indemnification 33\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n14.2 Indemnification of Customer 33\n14.3 Intellectual Property Indemnity 34\n14.4 Indemnification Procedure 34",
    "Article 14 Indemnification 33\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n14.2 Indemnification of Customer 33\n14.3 Intellectual Property Indemnity 34\n14.4 Indemnification Procedure 34\nArticle 15 Insurance 35\n15.1 Insurance Coverage 35\n15.2 Evidence of Insurance 35\nArticle 16 Legal and Regulatory 35\n16.1 Compliance with Laws 35\n16.2 Maintenance of Records 36\n16.3 Notice of Reports 36\n16.4 Drug Master Files 36\n16.5 Compliance with Regulatory Standards 36\n16.6 Inspection 36\nArticle 17 Recalls 37\n17.1 Safety 37\n17.2 Recalls 37\n17.3 Supplier's Liability for Recall 37\n17.4 Customer's Liability for Recall 37\n17.5 Replacement Shipments 37\nArticle 18 Termination 38\n18.1 Termination 38\n18.2 Consequences of Termination 39\n18.3 Return of Samples 40\n18.5 Survival 40\nArticle 19 Miscellaneous 41\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n19.2 Change of Control 41\n19.3 Counterparts 41\n19.4 Dispute Resolution 41\n19.5 Force Majeure 42\n19.6 Performance 42",
    "Article 19 Miscellaneous 41\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n19.2 Change of Control 41\n19.3 Counterparts 41\n19.4 Dispute Resolution 41\n19.5 Force Majeure 42\n19.6 Performance 42\n19.7 Further Assurances 42\n19.8 Independent Contractors 42\n19.9 Injunctions 43\n19.10 Notices 43\n19.11 Entire Agreement 44\n19.12 Severability 44\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n[SECTION] BETWEEN:\nParatek Pharmaceuticals, Inc., a company having a place of business at 75 Park Plaza, 4t h Floor, Boston, MA 02116, USA (\"Customer\")\n[SECTION] AND:\nCARBOGEN AMCIS AG, a company having a place of business at Hauptstrasse 171, CH 4416 Bubendorf, Switzerland (\"Supplier\" and, collectively with Customer, the \"Parties\", and each, a \"Party).\n[SECTION] WHEREAS:\nA. Customer is the owner of certain technology and patent rights regarding the Product (as defined herein) having the description set out in Exhibit A (Description of Product) and Exhibit B (Chemical Synthesis);",
    "B. Customer has filed / intends to file for approval with the United States Food and Drug Administration and/or its foreign equivalents, an Investigational New Drug Application (\"IND\") and a New Drug Application (\"NDA\"), and/or the foreign equivalents thereof, for certain formulations containing the Product;\nC. Supplier is engaged in the business of performing contracted process development, Manufacturing and supply services of active pharmaceutical ingredients (\"APIs\") and intermediates; and\nD. Customer desires that Supplier Manufacture the Product in bulk quantities, and Supplier desires to perform such services, each on the terms and conditions set out in this Agreement.\nNOW THEREFORE, in consideration of the premises and the mutual covenants and agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows:\nArticle 1 Interpretation\n1.1 Definitions",
    "Article 1 Interpretation\n1.1 Definitions\nIn this Agreement, in addition to words and phrases defined where they are used, the following words and phrases shall have the following meanings:\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\nb) \"Agreement\" means this Supply Agreement for the Product, including all Exhibits attached hereto;\nc) \"Applicable Law\" means any applicable law, statute, rule, regulation, order, judgment or ordinance of any governmental or regulatory authority or agency;\nd) \"Applicable Regulatory Authority\" means FDA, EMEA and/or other equivalent governmental or regulatory authorities or agencies and any successors thereto;\ne) \"Business Day\" means any day on which banking institutions in Boston, Massachusetts and Bubendorf, Switzerland are open for business;\nf) \"Campaign\" means a schedule of one or more discrete batches of Product Manufactured in sequence by Supplier without pausing to change over to manufacture of any other product;",
    "f) \"Campaign\" means a schedule of one or more discrete batches of Product Manufactured in sequence by Supplier without pausing to change over to manufacture of any other product;\ng) \"cGMP Requirements\" means the current Good Manufacturing Practices standards required under ICH Q7A guideline and/or any similar standards of applicable governmental and/or regulatory authorities as defined in the Quality Agreement;",
    "h) \"Change of Control\" means any transaction or series of transactions wherein (a) the voting securities of Supplier outstanding immediately prior thereto cease to represent at least fifty percent (50%) of the combined voting power of the surviving entity immediately after such transaction or transactions; (b) the stockholders or equity holders of Supplier approve a plan of complete liquidation of Supplier, or an agreement for the sale or disposition by Supplier of all or substantially all of Supplier's assets, other than to an Affiliate; (c) a Third Party becomes the beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of Supplier; or (d) substantially all of Supplier's business or assets which relate to this Agreement are sold or otherwise transferred to a Third Party;",
    "i) \"Chemical Synthesis\" means established and reliable execution of chemical reactions in order to produce the \"Product\" by applying chemical and physical manipulations usually involving one or more reactions;\n(i) was known to the recipient or any of its Affiliates, as evidenced by its written records, before receipt thereof under this Agreement;\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n(iv) the recipient can demonstrate through competent written records is independently developed by or for the recipient or any of its Affiliates by individuals or entities who have not had access to the information disclosed under this Agreement.\nk) \"Customer Licensee\" means any Third Party to whom Customer grants a license or a right to research, develop, make, have made, use, sell, have sold, import, export or otherwise exploit a Product or Customer Product;\nl) \"Customer Material\" means the compound satisfying the Customer Material Specification;",
    "l) \"Customer Material\" means the compound satisfying the Customer Material Specification;\nm) \"Customer Material Specifications\" means the specifications for the Customer Material set forth in the Quality Agreement, as such may be amended from time to time in accordance with its terms;\nn) \"Customer Product\" means any pharmaceutical product owned, controlled or sold by Customer, its Affiliates or Customer Licensees that incorporates or is derived from a Product;\no) \"Customer Technology\" means:\n[* * *];\np) \"Drug Master File\" or \"DMF\" means a submission to the Applicable Regulatory Authority that provides detailed information about facilities, processes or articles used in the Manufacture, processing, packaging and storing of a drug or excipient, among others, in order to obtain appropriate Applicable Regulatory Authority approval for the production for that drug;\nq) \"EMEA\" means the European Medicines Agency and any successors thereto;",
    "q) \"EMEA\" means the European Medicines Agency and any successors thereto;\nr) \"FDA\" means the United States Food and Drug Administration and any successors thereto;\ns) \"FD&C Act\" means the Federal Food, Drug and Cosmetic Act, as the same may be amended or supplemented from time to time;\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\nw) \"Manufacture,\" \"Manufactured\" or \"Manufacturing\" means all activities involved in the production of Products to be supplied to Customer or its Affiliates hereunder, including the preparation, formulation, finishing, testing, storage and packaging for shipment of Products and the handling, storage and disposal of any residues or wastes generated thereby;\nx) \"Manufacturing Process\" means the activities set out in (a) this Agreement, (b) the Master Batch Record and (c) Supplier's standard operating procedures for the Manufacturing, characterization and testing, and bulk packaging and storage of the Product;",
    "y) \"Master Batch Record\" means the complete detailed Manufacturing and control instructions and specifications for the Manufacturing Process for the Product, as defined by the applicable validation protocol and cGMP Requirements, as may be amended from time to time; in accordance with cGMP Requirements, or by mutual agreement of both Customer and Supplier;\nz) \"Materials\" means any and all materials, reagents, chemicals, compounds, physical samples, models, specimens and any other similar physical substances that are used in the Manufacture of the Product except for Customer Materials, including processes and activities leading up to and peripheral to the Manufacture of the Product;\naa) \"Product\" means the compound product as described in Exhibit A satisfying the Product Specifications;\nbb) \"Product Specifications\" means the specifications for the Product set forth in the Quality Agreement, as such may be amended from time to time in accordance with its terms;",
    "bb) \"Product Specifications\" means the specifications for the Product set forth in the Quality Agreement, as such may be amended from time to time in accordance with its terms;\ncc) \"Quality Agreement\" shall mean that certain Quality Agreement Relating to Contract Manufacturing Services by and between Customer and Supplier, dated [* * *];\ndd) \"Recall\" means any action by Supplier, Customer or any of their respective Affiliates, to recover possession of the Product or finished products containing the Product shipped to Third Parties. \"Recalled\" and \"Recalling\" shall have comparable meanings;\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\ngg) \"Services\" refers to any activities undertaken by Supplier relating to the Product, as referenced in Section 6.6 (Services);\nhh) \"Supplier Technology\" means, to the extent such is not Customer Technology: [* * *];\nii) \"Term\" means the Initial Term and the Renewal Term, if applicable;",
    "hh) \"Supplier Technology\" means, to the extent such is not Customer Technology: [* * *];\nii) \"Term\" means the Initial Term and the Renewal Term, if applicable;\njj) \"Territory\" means the United States of America and its territories and possessions and any other countries in the world added to the definition of \"Territory\" pursuant to Section 3.10;\nkk) \"Third Party\" means any party other than a Party to this Agreement or an Affiliate of a Party to this Agreement; and\nll) \"Yield\" means, with respect to any batch of Product manufactured by Supplier under this Agreement, a percentage equal to the amount of Customer Material contained in such batch of Product delivered and accepted by Customer under this Agreement divided by the amount of Customer Material used in the Manufacturing Process of such batch of Product.\n1.2 Other Definitions\nAny words defined elsewhere in this Agreement shall have the particular meaning assigned to the words.\n1.3 Currency",
    "1.2 Other Definitions\nAny words defined elsewhere in this Agreement shall have the particular meaning assigned to the words.\n1.3 Currency\nIn this Agreement, all references to money or payments means U.S. Dollars and all payments made hereunder shall be made in that currency.\n1.4 Headings\nThe headings in this Agreement are solely for convenience of reference and shall not be used for purposes of interpreting or construing the provisions hereof.\n1.5 Exhibits\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\nThis Agreement shall be governed by and construed in accordance with the substantive Laws of the [* * *], excluding any rules of conflicts of laws that would apply the substantive laws of any other jurisdiction.\nArticle 2 Term\n2.1 Term\n[* * *]",
    "Article 2 Term\n2.1 Term\n[* * *]\nThis Agreement shall commence on the Effective Date and shall be valid until the [* * *] (the \"Initial Term\"). Both Parties shall use reasonably diligent efforts to come to a subsequent long-term agreement, including good faith negotiations regarding minimum volume-based Product commitments from Customer to Supplier, no later than [* * *] to replace this Agreement and serve as a long-term supply agreement between the Parties. Should the Parties have not agreed to the following agreement by [* * *], this Agreement shall automatically stay in force for a maximum of [* * *] (unless otherwise mutually agreed by the Parties or as otherwise set forth in Section 18.1(a)) or until the Parties have signed the follow-on agreement (the \"Renewal Term\").\n2.2 Effect of Expiration on Purchase Orders",
    "2.2 Effect of Expiration on Purchase Orders\nFor the avoidance of doubt, any signed Purchase Order which has not been completed at the date of expiry shall continue in effect unless cancelled in accordance with Section 6.4 or Article 18. For further avoidance of doubt, the terms and conditions of this Agreement shall remain applicable to any such signed Purchase Order which continues in effect.\nArticle 3 Supply of Product\n3.1 Supply of Product\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\nc) [* * *]\nd) In the event the Product manufactured and delivered to Customer under a Purchase Order is less than [* * *] of the amount ordered by Customer under such Purchase Order or if Customer otherwise reasonably requests, [* * *].\nd) For clarity, nothing in this Section 3.1 limits Supplier's liability under this Agreement or under law, including liability for negligence, willful misconduct and failure to comply with Product Specifications; [* * *].\n3.2 Manufacturing Services",
    "3.2 Manufacturing Services\nSupplier will make available its labor, equipment and Facilities for the Manufacture and characterization of the Product, including in-process and quality control analyses, release testing, storage and bulk packaging of the Product, and shipping of the Product, in accordance with the terms and conditions of this Agreement.\n3.3 Supply of Materials and Customer Material\na) Materials\n i. Supplier shall, at its cost, be responsible for the purchase, planning, supply, control, testing, release and compliance of all Materials (other than Customer Materials unless expressly otherwise set forth in this Agreement) required for the Manufacture of the Product and performance of Services under accepted Purchase Orders.",
    "ii. Supplier shall ensure that all Materials (other than Customer Material unless expressly otherwise set forth in this Agreement) used in the Manufacture of the Product and performance of Services shall comply with the specifications mutually agreed by the Parties in writing and applicable requirements of the Quality Agreement.\n iii. Supplier shall test and inspect all Materials as set forth in the Quality Agreement and Supplier's standard incoming inspection andtesting procedures, which at a minimum will include appearance and identity testing.\nb) Customer Material\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n ii. Customer or its designee (for which Customer is responsible) shall, at its cost, be responsible for the qualification of suppliers ofCustomer Materials.",
    "ii. Customer or its designee (for which Customer is responsible) shall, at its cost, be responsible for the qualification of suppliers ofCustomer Materials.\n iii. Customer or its designee (for which Customer is responsible) shall ensure that all Customer Materials used in the Manufacture of theProduct and performance of Services shall meet applicable requirements set forth in the Quality Agreement.\n iv. Supplier shall test and inspect all Customer Materials in accordance with the Quality Agreement and Supplier's standard incoming inspection and testing procedures. Supplier shall also independently release Customer Materials (but Supplier shall not use any Customer Materials that have not also been released by Customer).",
    "v. Upon receipt of a Purchase Order from Customer, Supplier will inform Customer of the latest delivery date required for Customer Materials [* * *]. Customer will use commercially reasonable efforts to coordinate delivery of Customer Materials by that date according to [* * *].",
    "vi. If Customer is unable to deliver Customer Materials by the date required by Supplier, this will be promptly communicated to Supplier. Supplier will use commercially reasonable efforts to reallocate capacity and accommodate the planned Campaign at a later date. [* * *] Supplier will be released from its obligation under the relevant Purchase Order and any associated penalties regarding delivery date for the corresponding Product. In the event of any such delay in the delivery of Customer Materials to Supplier, the Parties shall negotiate in good faith and agree upon a revised schedule for the supply of Products to Customer or its designee, which revised schedule shall be binding on Supplier in accordance with this Agreement.",
    "vii. In the event that Customer Materials delivered to Supplier are found by Supplier to be non-conforming to the Customer Material Specifications at the time of delivery of such Customer Materials to Supplier and Customer challenges this finding, the Parties shall conduct a joint investigation. If Supplier and Customer are unable to resolve the issue of non-compliance then a sample of the relevant Customer Material will be submitted to an independent laboratory reasonably acceptable to both Parties for testing against the Customer Material Specifications, and determination whether or not the Customer Material did not comply with the Customer Material Specifications at the time of delivery to Supplier",
    ". The test results of the independent laboratory testing shall be final and binding upon Customer and Supplier, and the fees and expense of such laboratory testing and the out-of-pocket costs reasonably incurred by the Parties in the joint investigation shall be [* * *] In such event, except as set forth in Section 3.3(b)(vi), Supplier shall be released from its obligation with respect to the relevant Purchase Order and any associated penalties regarding a delayed delivery date for the corresponding Product under such Purchase Order. In the event that Customer delivers any such non-conforming Customer Materials, the Parties shall negotiate in good faith and agree upon a revised schedule for the supply of Products to Customer or its designee, which revised schedule shall be binding on Supplier in accordance with this Agreement.",
    "Source: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n3.4 Production Capacity\nSupplier agrees to provide to Customer all such facility and Manufacturing capacity to perform the Manufacturing Process as required to meet the Product requirements as described in the then-current Short Term Rolling Forecast (as defined below). Supplier agrees that it shall provide to Customer at least [* * *] prior written notice of any scheduled shutdown at any Facility that may impact Supplier's ability to Manufacture and timely deliver the Product to Customer under this Agreement, [* * *].\nFor the avoidance of doubt, Supplier confirms that it has the capacity to deliver [* * *], or such adjusted amount as mutually agreed by the Parties. Batch size and annual capacity could be adjusted in the future by mutual agreement of the Parties based on results of ongoing scale up work.\n3.5 Processing Changes",
    "3.5 Processing Changes\na) Supplier shall not make any material changes to the Manufacturing Process, starting materials, the Master Batch Record or Product Specifications for the Manufacture of the Product except in accordance with the Quality Agreement. For clarity, formatting changes in the documentation related to the Master Batch Record shall not be deemed a \"material\" change under this Section 3.5(a).\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\nc) In the event of a change to the Manufacturing Process, the Master Batch Record or the Product Specifications, the relevant documents and related Exhibits to this Agreement will be revised accordingly.\nd) All operational Master Batch Records and standard operating procedures utilized by Supplier are in the German language. Any requirement by Customer for translation of such records will be billed at cost.\n3.6 Monitoring of Facilities\n3.7 Subcontracting",
    "Supplier shall obtain Customer's prior written approval, in accordance with the Quality Agreement, to use a subcontractor to perform services under this Agreement, such approval not to be unreasonably withheld, conditioned or delayed. Any and all such contractors shall perform such services in accordance with the terms and conditions of this Agreement, and Supplier shall remain liable for the performance of its obligations under this Agreement. Supplier may use the Third Party suppliers set forth in Schedule 4 of the Quality Agreement for such specific activities set forth opposite their respective name(s) in such Schedule. It is hereby agreed that Customer may authorize the use of additional Third Party suppliers under this Agreement in accordance with the Quality Agreement",
    ". It is hereby agreed that Customer may authorize the use of additional Third Party suppliers under this Agreement in accordance with the Quality Agreement. Supplier agrees to use the Third Party suppliers identified, as applicable, in Schedule 4 of the Quality Agreement as the exclusive suppliers of starting materials for the Product Manufacturing Process and any deviation from said supply sources requires the prior written approval of Customer, in accordance with the Quality Agreement, such approval not to be unreasonably withheld, conditioned or delayed.",
    "Source: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n3.10 Territory Expansion\nAt any time during the Term, Customer may provide written notice to Supplier of its intent to expand the Territory under this Agreement to include one or more additional countries or territories. Promptly following such notification, the Steering Committee (as defined below) shall meet to discuss any expansion of Supplier's Manufacturing capabilities necessitated by such expansion in accordance with clause (b) of Section 7.4 and the Parties shall execute an amendment that (a) amends the definition of \"Territory\" under clause jj) of Section 1.1 to include such additional countries or territories and (b) modifies the provisions of this Agreement as necessary in order to reflect the regulatory requirements of such additional countries or territories. For clarity, neither Party shall be obligated to amend the definition of Territory at any point during the Term.\n3.11 Supply to Customer Licensees",
    "3.11 Supply to Customer Licensees\nIn the event Customer delivers a written request to Supplier requesting that Supplier engage in negotiations with a Customer Licensee on the terms of a definitive agreement pursuant to which Supplier would Manufacture and supply Product to such Customer Licensee or a designee of a Customer Licensee, Supplier shall use commercially reasonable good faith efforts to negotiate and execute such agreement on substantially the same terms of this Agreement (including pricing, orders, forecasting, delivery, non-conformance, failure to supply, term and termination).\n3.12 Alternative Supply\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\nArticle 4 Forecasts\n4.1 Short Term Rolling Forecasts",
    "3.12 Alternative Supply\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\nArticle 4 Forecasts\n4.1 Short Term Rolling Forecasts\nCommencing on the Effective Date, Customer shall provide to Supplier on a calendar quarterly basis on or before the last Business Day of each calendar quarter during the Term, a short term rolling forecast for the [* * *] period commencing on the first day of the following calendar month (each, a \"Short Term Rolling Forecast\"). Each Short Term Rolling Forecast shall set out Customer's reasonable and genuine estimate of the quantities of the Product to be ordered by Customer and to be delivered by Supplier under this Agreement for the following [* * *].",
    "(A): In case of an order volume equal or less than [* * *]: The first [* * *] of each short term rolling forecast shall be binding firm purchase orders by Customer (each a \"Purchase Order\") and the last [* * *] of each short term rolling forecast shall be non-binding, good faith estimates. Customer shall provide Supplier with one or more Purchase Order(s) for Product consistent with the first [* * *] binding portion of each Short Term Rolling Forecast, at least [* * *] in advance of the scheduled delivery dates provided in such Purchase Order(s).",
    "(B): In case of order volume larger than [* * *]: The first [* * *] of each short term rolling forecast shall be binding firm purchase orders by Customer (each a \"Purchase Order\") and the last [* * *] of each short term rolling forecast shall be non-binding, good faith estimates. Customer shall provide Supplier with one or more Purchase Order(s) for Product consistent with the first [* * *] binding portion of each Short Term Rolling Forecast, at least [* * *] in advance of the scheduled delivery dates provided in such Purchase Order(s).\n4.2 Long Term Forecasts\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n5.1 Release Testing",
    "4.2 Long Term Forecasts\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n5.1 Release Testing\na) Supplier shall perform release testing of all batches of Product prior to delivery to Customer in accordance with the Product Specifications and the Master Batch Record, to determine whether such batches of Product meet the requirements set out in the Product Specifications. Customer shall be responsible for the final release of Product prior to shipping and further processing.\nb) Supplier shall ensure that:\n(i) its quality assurance department approves each batch of Product for release promptly following successful completion of release testing done by its quality control department (in this section \"promptly\" means [* * *]); and\n(ii) its quality assurance department does not release any batch of Product that does not meet the requirements set out in the Product Specifications without prior written consent of Customer.",
    "(ii) its quality assurance department does not release any batch of Product that does not meet the requirements set out in the Product Specifications without prior written consent of Customer.\nc) Supplier shall prepare a Certificate of Analysis and Certificate of Conformance, setting out the results of the release testing and which shall be included with each batch of Product shipped to Customer.\nd) Customer shall have the right to oversee the activities set forth in this Section 5.1 in accordance with the Quality Agreement.\n5.2 Additional Release Testing\nCustomer reserves the right to conduct, in its sole discretion and at its expense, additional analytical testing on the Product.\n5.3 Retention Samples\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017",
    "5.3 Retention Samples\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\nIf requested by Customer, Supplier shall be responsible for performing annual stability testing of the Product and shall ensure that all such testing is performed in compliance with the applicable ICH regulations (e.g. follow-up stability studies of commercially used products). Costs associated with annual stability testing will be quoted separately from commercial unit pricing under a separate Scope of Work or Purchase Order.\n5.5 Reference Standards\nIf requested by Customer, Supplier shall be responsible for qualification and requalification of reference standards. Costs associated with qualification and requalification of reference standards will be quoted separately from commercial unit pricing under a separate Scope of Work or Purchase Order.\n5.6 Preparation of Process Qualification",
    "5.6 Preparation of Process Qualification\nAll costs associated with the preparation of process qualification (as but not limited to analytical method validation, process optimization, PAR studies, preparation of quality risk assessments, preparation of validation protocols and report per stage, preparation of validation master protocol and report, preparation of process performance assessment) will be handled separately from the commercial unit pricing under separate Scopes of Work or Purchase Orders. Until otherwise agreed, all pricing for process qualification services to be similar to current framework between Supplier and Customer.\nArticle 6 Purchase Orders\n6.1 Placement of Purchase Orders",
    "Article 6 Purchase Orders\n6.1 Placement of Purchase Orders\nConsistent with the Short Term Rolling Forecast as set forth in Section 4.1, Customer shall place with Supplier Purchase Orders, stating Customer's required delivery data, anticipated delivery schedule and the anticipated Fees, in accordance with the Fee Schedule set out in Exhibit C, for each delivery of Product to be made under this Agreement. Purchase Orders must have at least [* * *] of lead time before anticipated delivery to allow sufficient time for Supplier's planning, raw material purchases, production and release. Each Purchase Order shall constitute a firm, binding order, upon Supplier's acceptance thereof in accordance with Section 6.2.\n6.2 Acceptance of Orders\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017",
    "6.2 Acceptance of Orders\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\nIn the event the terms and conditions of this Agreement conflict with the terms and conditions of the Purchase Order, the terms and conditions of this Agreement shall take precedence unless otherwise agreed upon by the Parties.\n6.3 Delays",
    "6.3 Delays\nIf, after acceptance of a Purchase Order, Supplier is unable for any reason to supply quantities of the Product in accordance with the Purchase Orders placed by Customer under Section 6.1 on the timelines set forth therein, Supplier shall inform Customer within [* * *] of becoming aware of its inability to supply the Product of the expected duration of such inability and shall keep Customer informed on a timely basis of developments during any such period of time. The Parties shall cooperate to expedite the scheduling of the resumption of Manufacture of the Product by Supplier when any such inability has been alleviated. In the event of any delay in delivery of Product from the delivery date on the applicable Purchase Order for such Product, if such delay is: [* * *].\n6.4 Cancellation of Purchase Orders",
    "6.4 Cancellation of Purchase Orders\nIn the event that Customer cancels all or part of a Purchase Order already accepted by Supplier, Supplier will use best efforts to reallocate capacity and mitigate any resultant costs of such cancellation. Except as expressly set forth in Section 3.4, Section 6.2, Section 6.3 and Section 6.5, the following will be charged to Customer:\n[* * *]\n6.5 Material Failure of Supply\nIf Supplier, for any reason, fails to supply at least [* * *] of the units of Product ordered by Customer pursuant to valid Purchase Orders during any period of [* * *] or longer beginning on the requested delivery date, in addition to and without limiting any other remedies available to Customer, [* * *].\n6.6 Services\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n[* * *]\nArticle 7 Shipment of Product\n7.1 Storage of Product",
    "6.6 Services\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n[* * *]\nArticle 7 Shipment of Product\n7.1 Storage of Product\nSupplier shall ensure that all Product held in storage is stored in accordance with the Product Specifications until shipped to Customer under this Agreement and that all storage areas meet cGMP Requirements. [* * *]\nShould any Product, during storage, change chemical composition, then Supplier and Customer will agree upon a plan for disposition of the Product, including possible disposal, reworking or using the Product \"as is.\" For clarity, Supplier shall not commence any action set forth in the preceding sentence until such a plan has been agreed by Customer. The cost of reworking the Product shall be borne by [* * *].\nThe cost of storage, monitoring (including any on-going analytical analysis), and insurance before shipment shall be borne by [* * *].\n7.2 Release and Shipment of Product",
    "The cost of storage, monitoring (including any on-going analytical analysis), and insurance before shipment shall be borne by [* * *].\n7.2 Release and Shipment of Product\na) Supplier shall notify Customer by facsimile or electronic transmission of each batch of Product Manufactured by it under this Agreement in accordance with this Article 7 as soon as reasonably possible, and no later than [* * *], after Supplier's quality assurance department approves the batch for release following successful completion of the release testing procedures.\nb) Supplier shall pack and label shipping boxes and ship all orders of Product in a prompt and timely manner and in accordance with international transport guidelines and regulations, the Product Specifications, and Customer's reasonable written instructions including, as applicable, for such shipment and the terms of this Agreement.",
    "c) Supplier shall not sell or otherwise dispose of any Product except in accordance with the terms and conditions of this Agreement.\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n7.3 Documentation\nSupplier shall include with each shipment of Product shipped to Customer under Section 7.2:\na) commercially appropriate documentation;\nb) a Certificate of Analysis and Certificate of Compliance in English for each batch of Product included in the shipment, in the forms set out in Exhibit D; and\nc) a copy of any deviation or investigation reports concerning each batch of Product shipped (to be sent separately from shipment as part of the batch record documentation).\n7.4 Steering Committee",
    "The Parties agree to form a steering committee (the \"Steering Committee\") to oversee their interactions under this Agreement as provided herein. Each Party shall name a mutually agreed upon equal number of representatives to the Steering Committee, which shall meet either in person or remotely (as mutually agreed) at least [* * *], or as otherwise mutually agreed by the Parties. The primary function of the Steering Committee is to ensure the ongoing communication between the Parties and discuss and resolve any issues arising under this Agreement",
    ". The Steering Committee shall in particular have responsibility for the following: (a) reviewing key metrics for the Product's production and quality, and reviewing and monitoring any required remediation with respect to production and quality for the Product; (b) reviewing Supplier's capacity and short-term and long-term planning for clinical and commercial supply of the Product, including anticipating any capacity shortfalls and discussing the cost allocation of investments required to increase capacity or improve efficiencies; (c) [* * *]; (d) reviewing and discussing draft Scopes of Work; (e) discussing the cost allocation, if any, of extraordinary costs incurred by Supplier in connection with the Manufacture of Products or provision of Services; and (f) establishing resource priorities and resolving resource conflicts.",
    "Article 8 Acceptance of Shipments\n8.1 Acceptance of Shipments\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\nThe failure of Customer or its designees to notify Supplier of any Out Of Specification Product in the manner set forth herein above shall constitute confirmation of the acceptance thereof.\n8.2 Dispute of Rejected Product",
    "8.2 Dispute of Rejected Product\nSupplier may, at its option, within [* * *] of receipt of any Notice of Rejection under Section 8.1, challenge the Notice of Rejection by delivering written notice thereof to Customer. In the event that Supplier challenges the Notice of Rejection, Customer and Supplier shall conduct a joint investigation. If Supplier and Customer are unable to resolve the issue of non-compliance then a sample of the Product will be submitted to an independent laboratory reasonably acceptable to both Parties for testing against the Product Specifications, and determination whether or not the non-compliance may be caused by a fault on the part of Supplier. The test results of the independent laboratory testing shall be final and binding upon Customer and Supplier, and the fees and expense of such laboratory testing shall be borne entirely by the Party against whom such laboratory's findings are made.\n8.3 Remedies",
    "8.3 Remedies\na) Except as set forth in this Agreement, in the event of a Product shortage[* * *].\nb) In the event that Customer issues a timely Notice of Rejection in respect to any Out Of Specification Product:\n[* * *]\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n9.1 Fees\na) Customer shall pay to Supplier, in respect of each Purchase Order placed by Customer, the applicable Fees for the supply of the Product in bulk quantities under this Agreement, in accordance with the terms of this Agreement.\nb) Except as otherwise expressly provided in this Agreement, the Fees specified in each Purchase Order accepted by Supplier shall be full compensation for all Manufacturing and characterization activities and Materials in respect thereof. Customer shall make all requests for processing changes to be performed under this Agreement in writing under Section 3.5 and Supplier shall provide Customer a cost estimate for such work.\n9.2 Adjustments to Fees",
    "9.2 Adjustments to Fees\nDuring the Term of this Agreement, either Party may request an increase or decrease of the Fees specified in Exhibit C no more than [* * *] and such change in Fees shall take effect on [* * *] for which such Fee change is requested. Such change in Fees may be requested due to any of the following events:\n[* * *] or\n(iii) any other cost adjustments mutually agreed to by the Parties via the Steering Committee.\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017",
    "[* * *] or\n(iii) any other cost adjustments mutually agreed to by the Parties via the Steering Committee.\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\nThe Fees shall be exclusive of any taxes, customs duties, levies and other charges applicable to the supply of the Product under this Agreement (\"Taxes\"). Customer shall pay any Taxes and reimburse Supplier for any Taxes for which Customer is responsible but which have been paid by Supplier. Subject to compliance with laws, the Parties shall reasonably cooperate to eliminate or minimize the amount of any such Taxes imposed on the transactions contemplated in this Agreement. For clarity, Customer shall not be liable for any taxes incurred by the Supplier including, without limitation, income taxes, employment taxes, use taxes, and the like incurred by Supplier, or for any penalties or interest related to the failure of Supplier to collect sales, use, VAT or similar taxes.\nArticle 10 Invoicing and Payment",
    "Article 10 Invoicing and Payment\n10.1 Issuance of Invoices\nSupplier shall, in accordance with Section 10.2, invoice Customer for each Purchase Order accepted under Section 6.2 as follows:\n10.2 Invoice Contents\nAll invoices issued by Supplier under Section 10.1 shall show:\na) the actual quantity of Product shipped;\nb) the lot number of each batch of Product shipped;\nc) the Fees for the quantity of Product shipped, based on the Fees for the Product set out in the applicable Purchase Order; and\nd) the Purchase Order number placed by Customer for the Product shipped.\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\nIf Customer delays shipment of Product released by Supplier in accordance with Section 7.2, Supplier may issue its invoice under Section 10.1 on or after the release, with reference to the Product released under Section 10.2.\n10.4 Payment of Invoices",
    "10.4 Payment of Invoices\nEach invoice provided by Supplier to Customer under Section 10.1, to the extent accurate, shall be paid by Customer to Supplier within [* * *] after the date of the invoice to the extent that Customer does not reasonably dispute that portion of the invoice in good faith.\nAll payments will be made in U.S. Dollars by SWIFT bank transfer directly to the Supplier account as specified in the respective Purchase Orders.\nArticle 11 Intellectual Property\n11.1 Title\nb) Supplier shall not knowingly use in the Manufacturing Process any Intellectual Property protected by any patent or patent application licensed to Supplier by any Third Party, except with the prior written consent of Customer.\n11.2 No Grant of Rights\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n11.4 Ownership of Inventions",
    "11.2 No Grant of Rights\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n11.4 Ownership of Inventions\nWith respect to any ideas, innovations, Improvements or inventions (whether patentable or non-patentable) developed by Supplier during the Term of this Agreement and [* * *], the Parties agree that, as between Customer and Supplier, Customer shall own all Rights to such Inventions and may obtain patent, copyright, and other proprietary protection respecting such Inventions. Supplier agrees to promptly disclose any Inventions to Customer. Supplier agrees to assign (and cause its employees or permitted subcontractors to assign), and does hereby assign, any and all rights, title and interests of Supplier in, to or under any Inventions to Customer. [* * *]\n11.5 Patents to Inventions\nWith respect to all Intellectual Property created or developed under this Agreement, [* * *].\n11.6 No Use of Trademarks",
    "11.5 Patents to Inventions\nWith respect to all Intellectual Property created or developed under this Agreement, [* * *].\n11.6 No Use of Trademarks\nNothing contained herein shall give either Party any right to use any trademark of the other Party. All trademarks and service marks adopted by Customer to identify the Product or a Customer Product are and shall remain the property of Customer.\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n12.2 Disclosure with Consent\n12.3 Publicity\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017",
    "Source: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n12.2 Disclosure with Consent\n12.3 Publicity\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n(b) Supplier further covenants and agrees that, (i) with respect to any future Supplier Employee, Supplier or its Affiliate shall enter into a binding written arrangement with such Supplier Employee as set forth in Section 12.5(a) and (ii) with respect to any binding written arrangement referred to in this Section 12.5(b) or Section 12.5(a), Supplier shall enforce, to the fullest extent permitted under Applicable Law, the terms and provisions of such arrangement.\n12.6 Duration of Obligation\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n13.1 Supplier's Representations, Warranties and Covenants\nSupplier hereby represents, warrants and covenants to Customer as follows:",
    "Source: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n13.1 Supplier's Representations, Warranties and Covenants\nSupplier hereby represents, warrants and covenants to Customer as follows:\na) Supplier has been duly organized and is validly subsisting and in good standing in its jurisdiction of organization and has the power to carry on the business as now being conducted by it;\nb) the execution, delivery and performance of this Agreement by Supplier have been duly authorized by all requisite corporate action and do not require any shareholder action or approval;\nc) Supplier has the right and authority to enter into this Agreement and perform its obligations hereunder, and this Agreement is a legal and valid obligation binding upon Supplier and enforceable in accordance with its terms;",
    "d) Supplier has not made and will not make any commitments to Third Parties inconsistent with or in derogation of Supplier's obligations under this Agreement and Supplier is to its knowledge not subject to any obligations that would prevent it from entering into or carrying out its obligations under this Agreement, and Supplier's compliance with the terms and provisions hereof does not and will not conflict with or result in a breach of any of the terms and provisions of or constitute a default under (i) a loan agreement, guaranty, financing agreement, agreement affecting a Product or other agreement or instrument binding or affecting it or its property; (ii) the provisions of its charter or operative documents or by-laws; or (iii) any order, writ, injunction or decree of any court or governmental authority entered against it or by which any of its property is bound;\ne) Supplier shall comply with all Applicable Law relating to its activities under this Agreement;",
    "e) Supplier shall comply with all Applicable Law relating to its activities under this Agreement;\nf) all Product delivered to Customer under this Agreement will have been Manufactured, stored and shipped in a competent fashion in accordance with the Master Batch Record, the Product Specifications, this Agreement, the Quality Agreement, Applicable Law and cGMP Requirements by qualified personnel and, to Supplier's knowledge, will be free from defects;\ng) the Facilities, including equipment, systems, utilities and services, complies with cGMP Requirements for the Manufacture of the Product under this Agreement;\nh) the Facilities and Supplier's procedures and processes in the Facilities are in compliance with Applicable Law, including applicable environmental, health and safety requirements, for the Manufacture of the Product under this Agreement;",
    "i) Supplier does not, at any time from and after the Effective Date, retain or use the services of (i) any person debarred under 21 U.S.C.  335a or (ii) any person who has been convicted of a crime as defined under the FD&C Act, in each case in any capacity associated with or related to the Manufacture or supply of Products or any service rendered to Customer under this Agreement or the Quality Agreement;\nj) all Product supplied by Supplier under this Agreement shall be delivered by it free and clear of any security interests, liens, claims, pledges or encumbrances of any kind or nature except for such as are created by Customer; and\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n13.2 Customer's Representations, Warranties and Covenants\nCustomer hereby represents, warrants and covenants to Supplier as follows:",
    "Source: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n13.2 Customer's Representations, Warranties and Covenants\nCustomer hereby represents, warrants and covenants to Supplier as follows:\na) Customer has been duly organized and is validly subsisting and in good standing in its jurisdiction of organization and has the power to carry on the business as now being conducted by it;\nb) the execution, delivery and performance of this Agreement by Customer have been duly authorized by all requisite corporate action and do not require any shareholder action or approval;\nc) Customer has the right and authority to enter into this Agreement and perform its obligations hereunder, and this Agreement is a legal and valid obligation binding upon Customer and enforceable in accordance with its terms;",
    "d) Customer has not made and will not make any commitments to Third Parties inconsistent with or in derogation of Customer's obligations under this Agreement and Customer is not subject to any obligations that would prevent it from entering into or carrying out its obligations under this Agreement, and Customer's compliance with the terms and provisions hereof does not and will not conflict with or result in a breach of any of the terms and provisions of or constitute a default under (i) a loan agreement, guaranty, financing agreement, agreement affecting a Product or other agreement or instrument binding or affecting it or its property; (ii) the provisions of its charter or operative documents or by-laws; or (iii) any order, writ, injunction or decree of any court or governmental authority entered against it or by which any of its property is bound;\ne) Customer shall comply with all Applicable Law relating to its activities under this Agreement; and",
    "e) Customer shall comply with all Applicable Law relating to its activities under this Agreement; and\nf) to Customer's knowledge, [* * *].\n13.3 No Other Warranty\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\na) [* * *], IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR ANY SPECIAL, CONSEQUENTIAL, PUNITIVE, INCIDENTAL OR INDIRECT DAMAGES, OR LOST PROFITS, HOWEVER CAUSED, ON ANY THEORY OF LIABILITY. THIS LIMITATION WILL APPLY EVEN IF THE OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE.\nb) EXCEPT AS SET FORTH BELOW IN THIS SECTION 13.4(b), IN NO EVENT WILL SUPPLIER'S LIABILITY, [* * *], BE GREATER THAN, PER CLAIM OR SERIES OF CLAIMS ARISING FROM THE SAME CAUSE OF ACTION, [* * *].\nEXCEPT AS SET FORTH BELOW IN THIS SECTION 13.4(b), [* * *], AS APPLICABLE, IN NO EVENT SHALL A PARTY'S LIABILITY, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, BE GREATER THAN, PER CLAIM OR SERIES OF CLAIMS ARISING FROM THE SAME CAUSE OF ACTION, [* * *].",
    "EXCEPT AS SET FORTH BELOW IN THIS SECTION 13.4(b), WITH RESPECT [* * *], IN NO EVENT SHALL A PARTY'S LIABILITY BE GREATER THAN, PER CLAIM OR SERIES OF CLAIMS ARISING FROM THE SAME CAUSE OF ACTION, [* * *].\nNOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS SECTION 13.4(b), WITH RESPECT TO [* * *] IN NO EVENT SHALL SUPPLIER'S LIABILITY, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, BE GREATER THAN, PER CLAIM OR SERIES OF CLAIMS ARISING FROM THE SAME CAUSE OF ACTION, [* * *].\n[* * *]\nArticle 14 Indemnification\n14.1 Indemnification of Supplier",
    "[* * *]\nArticle 14 Indemnification\n14.1 Indemnification of Supplier\nCustomer shall indemnify, defend and hold harmless Supplier and its officers, directors, agents, servants and employees against any and all actions, claims, demands, proceedings, suits, losses, damages, costs and expenses (including reasonable legal fees) of Third Parties (in this Article 14, \"Claims\") (including Claims for personal injury or death) to the extent such Claims result from or arise out of (a) any product liability claim directly related to Customer's commercial use, sale or distribution of Products or (b) Customer's [* * *] acts or omissions or [* * *], except, in each case of clause (a) and (b), to the extent Supplier has an obligation to indemnify Customer pursuant to Section 14.2 or 14.3.\n14.2 Indemnification of Customer\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n14.3 Intellectual Property Indemnity",
    "Customer (an \"Indemnifier\") shall indemnify, defend and hold harmless Supplier and the Supplier Representatives (each, an \"Indemnified Party\") from any and all Claims of any Third Party that any Intellectual Property (including, without limitation, Customer Materials, Product Information, Product Specifications, Customer Technology or Tufts Technology), provided by Customer to Supplier hereunder, infringes a Third Party's Intellectual Property Rights or otherwise violates a Third Party's rights",
    ". Supplier (an \"Indemnifier\") indemnifies Customer and its Affiliates and Customer Licensees, and their respective officers, directors, agents, servants, employees and consultants (each, an \"Indemnified Party\") from any and all Claims of any Third Party that the Intellectual Property (other than the Intellectual Property Customer has provided to Supplier under this Agreement) that Supplier elects to use in conducting the activities set out in this Agreement, infringes such Third Party's Intellectual Property Rights or otherwise violates a Third Party's rights.",
    "The Indemnifier's obligation to indemnify the Indemnified Party shall apply only upon the following terms and conditions:\na) the obligation shall only pertain to the Intellectual Property the Indemnifier, its Affiliates, officers, directors, agents, servants, employees or consultants elect to use in conducting the activities set out in this Agreement, and not to any Improvements or additions made by anyone other than the Indemnifier, whether with or without permission; and\nb) [* * *]\n14.4 Indemnification Procedure\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\nArticle 15 Insurance\n15.1 Insurance Coverage\nCustomer and Supplier each represent that they are sufficiently insured against any liability arising under this Agreement. Further, Supplier shall at a minimum retain [* * *].\n15.2 Evidence of Insurance",
    "15.2 Evidence of Insurance\nEach of Customer and Supplier shall, upon request by the other, provide the other Party with a copy of all insurance policies maintained under this Article 15 relating to the Manufacture of the Product in bulk quantities and the facilities therefor and shall notify the other Party in writing at least 30 days prior to the cancellation of or any material change to such insurance policies. Each Party may request that the other Party procure and maintain such additional insurance coverage relating to the Manufacture of the Product and the facilities therefore as may be reasonably necessary in respect of the Parties' respective obligations under this Agreement.\nArticle 16 Legal and Regulatory\n16.1 Compliance with Laws\na) Each Party shall, in connection with its obligations, rights and duties under this Agreement and in Manufacturing, handling, storage, loading, shipping, using, commercializing, reselling and distributing the Product:",
    "(i) comply with all Applicable Law or other requirements applicable to such Party's business; and\n(ii) subject to Subsection b) below, obtain and maintain in full force and effect all applicable licenses, permits, certificates, authorizations or approvals from local governmental authorities necessary to conduct its business and the activities contemplated under this Agreement. Such licences or certificates are to be provided to the other Party on request.\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017",
    "Source: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\nSupplier shall maintain adequate books and records and retention samples consistent with cGMP Requirements and any other Applicable Law and requirements of applicable governmental or regulatory authorities, in respect of test records, samples and associated support data for all batches of Product Manufactured by Supplier sufficient to substantiate and verify Supplier's duties and obligations under this Agreement for [* * *] from the expiration date of the respective Product batch.\n16.3 Notice of Reports\n16.4 Drug Master Files\nSupplier will routinely update and keep current all information pertinent to maintain the Drug Master Files relating to the Manufacture of the Product at the production site of Supplier. Supplier will fully support and reasonably assist Customer with its filing of any application with respect to the Product with any Applicable Regulatory Authority at Customer's expense.",
    "16.5 Compliance with Regulatory Standards",
    "Supplier shall be responsible for Manufacturing the Product in compliance with Applicable Law, cGMP Requirements and the standards of any other applicable governmental or regulatory authority. Each Party will provide reasonable assistance to the other, at no charge, if necessary to respond to audits, inspections, inquiries, or requests of any Applicable Regulatory Authority. Supplier shall advise Customer immediately if Supplier receives notice of an impending inspection related to a Product or if an authorized agent of any Applicable Regulatory Authority or other governmental agency provides advance notice of any investigation, inspection or visit to a Facility. In such event, Supplier shall permit, to the extent permitted by Applicable Law, Customer or its representatives to be present during such visit, at Customer's expense. Upon Customer's request, Supplier shall provide Customer with a copy of any report issued by such Regulatory Authority following such visit.\n16.6 Inspection",
    "16.6 Inspection\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n17.1 Safety\nSupplier shall provide Customer with reasonable co-operation to help Customer investigate adverse events or product complaints involving or related to the Product. The cost and expense of any testing undertaken by Supplier at Customer's request shall be borne by [* * *].\n17.2 Recalls",
    "17.2 Recalls\nIf either Party has grounds to recommend a Recall or otherwise receives a notification or information which might result in a Recall, the Party recommending such Recall or receiving such notification or information shall immediately notify the other Party in writing. Subject to Applicable Law, Customer and its designees shall have the sole responsibility to implement any Recall of the Product or any intermediate or finished product containing the Product and the sole right to make all final decisions regarding any such Recall. Supplier shall reasonably cooperate with Customer and its designees in implementing any such Recall, at Customer's expense.\n17.3 Supplier's Liability for Recall\nIn the event of a Recall or Seizure arising from [* * *], Supplier shall be liable for the expenses and out-of-pocket costs actually incurred by Customer as a result of such Recall or Seizure, and Supplier shall, at the option of Customer:\n[* * *].",
    "[* * *].\nSuch liability shall not limit or otherwise be exclusive of any other provisions of this Agreement.\n17.4 Customer's Liability for Recall\nIn the event of a Recall or Seizure arising from [* * *] Customer shall [* * *].\nSuch liability shall not be exclusive of any other provisions of this Agreement.\n17.5 Replacement Shipments\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n18.1 Termination\nThis Agreement is effective as of the Effective Date and will expire in accordance with Section 2.1, unless, upon the occurrence of any of the following events, this Agreement is earlier terminated in accordance with this Section 18.1:\na) Customer delivers written notice of termination to Supplier at least [* * *] prior to the expiration date of the Initial Term, which termination shall be effective as of the expiration date of the Initial Term;",
    "b) either Party delivers written notice of termination to the other Party at least [* * *] prior to the expiration date of the Renewal Term, which termination shall be effective as of the expiration date of the Renewal Term;\nc) a Party makes a general assignment for the benefit of creditors, a court of competent jurisdiction declares a Party insolvent or bankrupt, or a petition in bankruptcy or under any insolvency law is filed by or against a Party and such petition is not dismissed within [* * *] after it has been filed, and the other Party delivers written notice of termination to such Party, which termination shall be effective immediately upon delivery of such written notice;\nd) a Party breaches a material provision of this Agreement, and the other Party delivers written notice of termination to such breaching Party:\n(i) if the breach is not cured within [* * *] after written notice thereof to the Party in default; or",
    "(i) if the breach is not cured within [* * *] after written notice thereof to the Party in default; or\n(ii) if the breach is of a type that cannot be cured within [* * *], if a cure is not promptly commenced and diligently pursued until complete remediation but in any case after [* * *] unless otherwise agreed in writing between the Parties;\ne) any governmental law, regulation or order is adopted and made effective which would make performance of a Party's obligations under this Agreement impossible or commercially impracticable, and such Party delivers written notice of termination to the other Party, which termination shall be effective immediately upon delivery of such written notice; or\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\nOn expiration or the effective date of termination of this Agreement, if earlier:",
    "Source: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\nOn expiration or the effective date of termination of this Agreement, if earlier:\na) both Parties shall be released from all obligations and duties imposed or assumed hereunder, except obligations and liabilities previously accrued and as expressly provided by this Agreement, including, without limitation, those provisions which expressly survive termination or expiration of this Agreement;\nb) all Rights granted by Customer to Supplier under Section 11.3 shall immediately revert to Customer, provided that Supplier may continue to use any such Rights in order to fulfil its surviving obligations under Section 18.5, and only for such purpose;\nc) Supplier shall provide to Customer, to the extent they exist, copies of:\n(i) Supplier's Manufacturing batch records and analytical reports relating to the Product; and\n(ii) any other documents required to be delivered pursuant to this Agreement or otherwise reasonably requested by Customer;",
    "d) Unless this Agreement is terminated by Customer pursuant to Section 18.1(d) above, all Purchase Orders and Scopes of Work shall automatically be deemed terminated by Customer and Supplier shall be compensated for final Product already produced or Services already rendered in accordance with this Agreement and, for Products or Services not yet produced or rendered, as the case may be, Supplier shall be entitled to its fees, expenses and costs as set forth in Sections 6.4 and 6.6. Additionally, Customer shall be entitled to request that (i) all Products and/or works in process for which Customer has compensated Supplier and (ii) all Customer Materials be shipped to Customer in accordance with the provisions of Section 7.2(d)",
    ". If this Agreement is terminated by Customer pursuant to Section 18.1(d) as a result of Supplier's breach, then, Customer shall be able to elect whether Purchase Orders or Scopes of Work not yet completed at the date of termination or expiration should continue in force, subject to the terms and conditions herein; and",
    "Source: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\nOn expiration or earlier termination of this Agreement, unless otherwise instructed by Customer, Supplier shall, within [* * *], return to Customer all samples or other supplies of the Product (for which Supplier has been paid) in its possession or control in any form, with the exception of any samples such as retention samples that Supplier may be required to keep according to Applicable Law. The cost of returning any such supplies shall: [* * *]\nOn expiration or earlier termination of this Agreement, unless otherwise agreed between the Parties, each Party shall:\nb) upon written request of the other Party,\n18.5 Survival",
    "b) upon written request of the other Party,\n18.5 Survival\nExcept as otherwise provided herein or agreed in writing between the Parties, expiration or early termination of this Agreement shall not relieve either Party of its obligations incurred prior to such expiration or early termination, including the obligation to Manufacture and deliver the Product under Purchase Orders placed by Customer and accepted by Supplier prior to the effective date of expiration or earlier termination, and the obligation to pay Fees in respect thereof. In addition, the following provisions shall survive any expiration or early termination of this Agreement in accordance with the terms of such provision; provided that if there is no express expiration or termination of an obligation or a right under a surviving provision, such provision or right shall continue to survive, subject to Applicable Law[* * *]:\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017",
    "Source: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\nFurther, Article 8 (Acceptance of Shipments) shall survive any expiration or termination of this Agreement solely with respect to shipments of Product shipped prior to the effective date of expiration or termination.\nArticle 19 Miscellaneous\n19.1 Assignment; Inurement\nThis Agreement shall be binding upon and shall inure to the benefit of the Parties hereto and their successors and permitted assigns. Supplier shall not assign this Agreement, in whole or in part, to any person without the prior written consent of Customer, except to a Third Party which acquires all, or substantially all, of Supplier's business or assets, whether through merger or otherwise.",
    "Customer shall be entitled to assign this Agreement, in whole or in part, to any person without the consent of Supplier, provided that (i) such person acquires all, or substantially all, of Customer's business or assets with respect to the Product, whether through merger or otherwise; (ii) such person is an Affiliate of Customer or a Customer Licensee; or (iii) Customer remains liable for any payments Supplier is or will be entitled to under this Agreement. Customer shall not assign this Agreement, in whole or in part, to any other person without the prior written consent of Supplier, not to be unreasonably withheld, conditioned or delayed.\n19.2 Change of Control\nDuring the Term, Supplier will promptly notify Customer in writing if at any time a Change of Control shall occur as to Supplier, such notification to be given no later than fifteen (15) days following such Change of Control. [* * *]\n19.3 Counterparts",
    "19.3 Counterparts\nThis Agreement may be executed in any number of counterparts each of which shall be deemed to be an original and all of which taken together shall be deemed to constitute one and the same instrument.\n19.4 Dispute Resolution\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n19.5 Force Majeure",
    "Any delay or inability to perform any of the duties or obligations of either Party caused by an event outside the affected Party's reasonable control shall not be considered a breach of this Agreement, and unless provided to the contrary herein, the time required for performance shall be extended for a period equal to the period of such delay. Such events shall include, without limitation: acts of God; any governmental act or regulation; insurrections; riots or civil disturbance; acts of war; embargoes; labor disputes at facilities of Material suppliers, including strikes, lockouts, job actions, or boycotts; fires; explosions; terrorist attacks; floods; or other unforeseeable causes beyond the reasonable control and without the fault or negligence of the Party so affected",
    ". In order to take the benefit of this section, the Party so affected shall give prompt notice [* * *] to the other Party of such cause, and shall take whatever reasonable steps are necessary to relieve the effect of such cause as rapidly as reasonably possible. If performance is affected for a cumulative period of more than [* * *], the non-affected Party may terminate this Agreement immediately by notice in writing to the affected Party.",
    "19.6 Performance\nEach Party agrees to perform its obligations under this Agreement, including under any Scope of Work, in a timely manner. Supplier shall allocate adequate resources to execute its obligations under this Agreement, including under each Scope of Work. Supplier represents and warrants that all Services shall be performed by qualified personnel in accordance with the highest industry standards.\n19.7 Further Assurances\nThe Parties shall both execute and deliver such further instruments and do such further acts as may be required to implement the intent of this Agreement.\n19.8 Independent Contractors\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017",
    "19.8 Independent Contractors\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\nEach Party agrees that the other Party may be irreparably damaged if any provision of this Agreement is not performed in accordance with its terms. Accordingly, notwithstanding Section 19.3, each Party will be entitled to apply for an injunction or injunctions to prevent breaches of any of the provisions of this Agreement by the other Party, without showing or proving any actual or threatened damage, notwithstanding any rule of law or equity to the contrary, and may specifically enforce such provisions by an action instituted in a court having jurisdiction. These specific remedies are in addition to any other remedy to which the Parties may be entitled at law or in equity.\n19.10 Notices",
    "19.10 Notices\nUnless otherwise provided herein, any notice required or permitted to be given hereunder or any proposal for any modification of this Agreement (hereinafter collectively referred to as the \"Correspondence\") shall be faxed, mailed by overnight mail, certified mail postage prepaid, or delivered by hand to the Party to whom such Correspondence is required or permitted to be given hereunder at the addresses set out below. If delivered by hand, any such Correspondence shall be deemed to have been given when received by the Party to whom such Correspondence is given and if faxed, any such Correspondence shall be deemed to have been given on the first Business Day following facsimile transmission, as evidenced by written and dated receipt of the receiving Party.\nIf to Supplier: CARBOGEN AMCIS AG Hauptstrasse 159-173 CH 4416 Bubendorf Switzerland Attention: CEO Telephone: + 41 61 935 5353 Facsimile: + 41 61 935 5300\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017",
    "Source: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n19.11 Entire Agreement\nThis Agreement, the Quality Agreement and all Exhibits attached hereto (as the same may be amended from time to time by the written agreement of the Parties) constitute the entire agreement between the Parties with respect to the subject matter hereof and supersede all other documents, agreements, verbal consents, arrangements and understandings between the Parties with respect to the subject matter hereof. This Agreement shall not be amended orally, but only by an agreement in writing, signed by both Parties that states that it is an amendment to this Agreement.\n19.12 Severability",
    "19.12 Severability\nIf any term or provision of this Agreement shall for any reason be held invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other term or provision hereof, and this Agreement shall be interpreted and construed as if such term or provision, to the extent the same shall have been held to be invalid, illegal or unenforceable, had never been contained herein.\n19.13 Waiver\nNo waiver or modification of any of the terms of this Agreement shall be valid unless in writing and signed by an authorized representative of the Parties hereto. Failure by either Party to enforce any rights under this Agreement shall not be construed as a waiver of such rights, nor shall a waiver by either Party in one or more instances be construed as constituting a continuing waiver or as a waiver in other instances.\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\nby its authorized signatory:\n/s/ William M. Haskel",
    "Source: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\nby its authorized signatory:\n/s/ William M. Haskel\nName: William M. Haskel\nTitle: Sr. Vice President\nDate: January 9, 2017\nCARBOGEN AMCIS AG by its authorized signatory:\n/s/ Silke Erbeck\nName: Silke Erbeck\nTitle: Senior Head of Commercial Products\nDate: 10.Jan.2017\n/s/ Dr. Stephan Fritschi\nStephan Fritschi\nVP Operations\n[SECTION] CARBOGEN AMCIS AG\n10.Jan.2017 [Signature page to Outsourcing Agreement]\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n[* * *]\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n[* * *]\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n[* * *]\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017\n[]\nSource: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017"
  ]
}